Want to see SE:NICA full AI Analyst Report?
NICA Stock Chart & Stats
kr0.74
kr0.03(1.43%)
At close: 4:00 PM EST
kr0.74
kr0.03(1.43%)
Day’s Range― - ―
52-Week Rangekr0.33 - kr2.25
Previous CloseN/A
Volume105.00
Average Volume (3M)713.59K
Market Cap
kr119.01M
Enterprise Valuekr176.85
Total Cash (Recent Filing)kr19.06M
Total Debt (Recent Filing)kr53.63M
Price to Earnings (P/E)1.1
Beta1.66
Next Earnings
Nov 26, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.35
Shares Outstanding328,769,840
10 Day Avg. Volume1,559,045
30 Day Avg. Volume713,591
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.04
Price to Sales (P/S)3.26
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr141.40M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSharp top-line growth indicates improving customer adoption and commercial traction. If sustained through pharma qualification cycles, higher-volume chromatography media sales could create a broader recurring revenue base.
Specialized Life Science MaterialsNanologica operates in specialized pharmaceutical and life science workflows where customers require engineered materials and technical performance. This focus can support customer integration and longer qualification-driven relationships.
Positive Equity And Asset BasePositive equity and a substantial asset base provide some financial foundation for continued product development and manufacturing investment. This offers more resilience than a balance sheet already showing negative equity.
Bears Say
Persistent Operating LossesRevenue growth has not yet translated into sustainable operating profitability. Continued negative gross and operating profit limits internal funding capacity and raises uncertainty over whether scale or pricing can support a durable business model.
Ongoing Cash BurnNegative operating and free cash flow show that operations still require external funding despite revenue expansion. If cash generation does not improve, the company may face recurring dilution or refinancing needs to sustain investment and operations.
Rising Financial LeverageHigher leverage increases financial risk while the operating business remains loss-making. Debt obligations can reduce flexibility for product development and amplify refinancing pressure if cash burn persists or pharmaceutical adoption takes longer.
Nanologica AB News
NICA FAQ
What was Nanologica AB’s price range in the past 12 months?
Nanologica AB lowest stock price was kr0.33 and its highest was kr2.25 in the past 12 months.
What is Nanologica AB’s market cap?
Nanologica AB’s market cap is kr119.01M.
When is Nanologica AB’s upcoming earnings report date?
Nanologica AB’s upcoming earnings report date is Nov 26, 2026 which is in 81 days.
How were Nanologica AB’s earnings last quarter?
Nanologica AB released its earnings results on Aug 31, 2026. The company reported -kr0.06 earnings per share for the quarter.
Is Nanologica AB overvalued?
According to Wall Street analysts Nanologica AB’s price is currently Overvalued.
Does Nanologica AB pay dividends?
Nanologica AB does not currently pay dividends.
What is Nanologica AB’s EPS estimate?
Nanologica AB’s EPS estimate is -0.03.
How many shares outstanding does Nanologica AB have?
Nanologica AB has 328,769,840 shares outstanding.
What happened to Nanologica AB’s price movement after its last earnings report?
Nanologica AB reported an EPS of -kr0.06 in its last earnings report. Following the earnings report the stock price went down -23.061%.
Which hedge fund is a major shareholder of Nanologica AB?
Currently, no hedge funds are holding shares in SE:NICA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanologica AB
Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science industry in China, India, the United State of America, and internationally. It offers NLAB Saga, a new generation silica for preparative chromatography; and SVEA, a pre-packaged columns for analytical chromatography; and high-performance liquid chromatography, a separation method based on different substances in a solution passing through a column at different paces. The company provides products for the analysis and purification of substances, with a focus on peptides drugs for the treatment of diabetes and obesity. Nanologica AB (publ) was incorporated in 2004 and is headquartered in Södertälje, Sweden.
Technical Analysis
Camurus AB
―
Xbrane Biopharma AB
―
Xspray Pharma AB
―
Spago Nanomedical AB
―
Nanexa AB
―